Cargando…

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis

Vaccines against SARS-CoV-2 have shown remarkable efficacy and thus constitute an important preventive option against coronavirus disease 2019 (COVID-19), especially in fragile patients. We aimed to systematically analyze the outcomes of patients with hematological malignancies who received vaccinat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gagelmann, Nico, Passamonti, Francesco, Wolschke, Christine, Massoud, Radwan, Niederwieser, Christian, Adjallé, Raissa, Mora, Barbara, Ayuk, Francis, Kröger, Nicolaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Article - Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335098/ https://www.ncbi.nlm.nih.gov/pubmed/34911284 http://dx.doi.org/10.3324/haematol.2021.280163

Ejemplares similares

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
por: Gagelmann, Nico, et al.
Publicado: (2021)

Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation
por: Massoud, Radwan, et al.
Publicado: (2021)

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation
por: Massoud, Radwan, et al.
Publicado: (2022)

Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients
por: Gagelmann, Nico, et al.
Publicado: (2023)

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection
por: Christopeit, Maximilian, et al.
Publicado: (2021)

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
por: Gagelmann, Nico, et al.
Publicado: (2023)

Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19
por: Niederwieser, Christian, et al.
Publicado: (2022)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
por: Srivastava, Barnali, et al.
Publicado: (2023)

Clinical features of hepatitis E infections in patients with hematologic disorders
por: Ghandili, Susanne, et al.
Publicado: (2022)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)

Abdominal emergency surgery in patients with hematological malignancies: a retrospective single-center analysis
por: von Kroge, Philipp H., et al.
Publicado: (2023)

Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021?
por: Gagelmann, Nico, et al.
Publicado: (2021)

Reply to Shao and Zhou
por: Gagelmann, Nico, et al.
Publicado: (2022)

Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML
por: Niederwieser, Christian, et al.
Publicado: (2021)

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
por: Gagelmann, Nico, et al.
Publicado: (2022)

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
por: Modemann, Franziska, et al.
Publicado: (2020)

Correction: Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
por: Modemann, Franziska, et al.
Publicado: (2021)

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis
por: Atagunduz, Isik Kaygusuz, et al.
Publicado: (2020)

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy
por: Berger, Susanna Carolina, et al.
Publicado: (2022)

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
por: Ayuk, Francis, et al.
Publicado: (2023)

Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2018)

Neoantigens in Hematologic Malignancies
por: Biernacki, Melinda A., et al.
Publicado: (2020)

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis
por: Gagelmann, Nico, et al.
Publicado: (2022)

Radiotheranostic Agents in Hematological Malignancies
por: Caers, Jo, et al.
Publicado: (2022)

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
por: Schriewer, Levin, et al.
Publicado: (2020)

P1024: IMPACT OF TP53 IN MYELOFIBROSIS UNDERGOING STEM CELL TRANSPLANTATION
por: Gagelmann, N., et al.
Publicado: (2022)

Typhim vi immunization assists to discriminate primary antibody responses in hematological malignancies
por: Ochoa-Grullón, J., et al.
Publicado: (2020)

Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
por: Gagelmann, Nico, et al.
Publicado: (2022)

Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies
por: Bergamaschi, Cristina, et al.
Publicado: (2022)

Natural Killer Cells Modulation in Hematological Malignancies
por: Baier, Céline, et al.
Publicado: (2013)

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019)

Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection
por: Heidenreich, Silke, et al.
Publicado: (2017)

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
por: Klausen, Uffe, et al.
Publicado: (2018)

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
por: Guo, Zilong, et al.
Publicado: (2021)

Primary Immunodeficiencies and Hematologic Malignancies: A Diagnostic Approach
por: Chandra, Sharat, et al.
Publicado: (2022)

The role of interleukin-15 in the development and treatment of hematological malignancies
por: Sindaco, Paola, et al.
Publicado: (2023)

Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis
por: Mannina, Daniele, et al.
Publicado: (2022)

T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies
por: Janelle, Valérie, et al.
Publicado: (2020)

Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies
por: Mancini, Stéphane J.C., et al.
Publicado: (2021)

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
por: Zhang, Xiaomin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oh57cdr7i7g3q0ghlf3f1ibo5b